RELMADA THERAPEUTICS, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relmada Therapeutics, Inc. (Nasdaq: RLMD) on January 5, 2021, reporting events occurring on December 31, 2020. The company is incorporated in Nevada and operates as a biopharmaceutical entity.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed is a severance payment obligation of $237,500 related to the departure of an executive officer.
Material Changes
The primary material event reported is the departure of Dr. Thomas Wessel, who served as Executive Vice President and Head of Research and Development, effective December 31, 2020. This represents a significant change in the company's senior leadership and research management structure.
Management Commentary and Contingencies
Management has confirmed that in accordance with Dr. Wessel's employment contract, the company will pay him severance totaling $237,500. No additional guidance, outlook, or risk factors were disclosed in this specific filing beyond the executive departure.
Investor Verification Checklist
- Verify the impact of Dr. Wessel's departure on the company's ongoing research and development pipeline.
- Confirm the accounting treatment and timing of the $237,500 severance payment in upcoming financial reports.
- Check for subsequent filings regarding the appointment of a replacement for the Head of Research and Development role.